MXPA04006003A - Derivados del acido fenilpropionico substituidos como agonistas al receptor alfa activado-proliferativo de peroxisoma (ppar) humano. - Google Patents
Derivados del acido fenilpropionico substituidos como agonistas al receptor alfa activado-proliferativo de peroxisoma (ppar) humano.Info
- Publication number
- MXPA04006003A MXPA04006003A MXPA04006003A MXPA04006003A MXPA04006003A MX PA04006003 A MXPA04006003 A MX PA04006003A MX PA04006003 A MXPA04006003 A MX PA04006003A MX PA04006003 A MXPA04006003 A MX PA04006003A MX PA04006003 A MXPA04006003 A MX PA04006003A
- Authority
- MX
- Mexico
- Prior art keywords
- ppar
- agonists
- acid derivatives
- activated receptor
- receptor alpha
- Prior art date
Links
- 101000741788 Homo sapiens Peroxisome proliferator-activated receptor alpha Proteins 0.000 title 1
- 101150014691 PPARA gene Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 102000054223 human PPARA Human genes 0.000 title 1
- YPGCWEMNNLXISK-UHFFFAOYSA-N hydratropic acid Chemical class OC(=O)C(C)C1=CC=CC=C1 YPGCWEMNNLXISK-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
- C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion proporciona el enantiomero S de un compuesto de la formula (I); en donde R1 representa 2, 4- difluorofenio o ciclohexilo asi como tambien las sales farmaceuticas aceptables, solvatos, formas cristalinas y profarmacos del mismo, a los proceso para la preparacion de tales compuestos, a su utilidad en el tratamiento de las condiciones clinicas incluyendo los desordenes de lipidos (dislipidemia) ya sea o no asociado con resistencia a la insulina, a los metodos para su uso terapeutico y a las composiciones farmaceuticas que contienen a los mismos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0104334A SE0104334D0 (sv) | 2001-12-19 | 2001-12-19 | Therapeutic agents |
| PCT/GB2002/005744 WO2003051822A1 (en) | 2001-12-19 | 2002-12-18 | Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04006003A true MXPA04006003A (es) | 2004-09-27 |
Family
ID=20286433
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04006004A MXPA04006004A (es) | 2001-12-19 | 2002-12-18 | Derivados del acido fenilpropionico substituidos como agonistas al receptor alfa activado-proliferativo de peroxisoma (ppar) humano. |
| MXPA04006003A MXPA04006003A (es) | 2001-12-19 | 2002-12-18 | Derivados del acido fenilpropionico substituidos como agonistas al receptor alfa activado-proliferativo de peroxisoma (ppar) humano. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04006004A MXPA04006004A (es) | 2001-12-19 | 2002-12-18 | Derivados del acido fenilpropionico substituidos como agonistas al receptor alfa activado-proliferativo de peroxisoma (ppar) humano. |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US7514471B2 (es) |
| EP (2) | EP1458673B1 (es) |
| JP (4) | JP3784804B2 (es) |
| KR (2) | KR20040074094A (es) |
| CN (3) | CN1293044C (es) |
| AR (2) | AR038047A1 (es) |
| AT (2) | ATE338743T1 (es) |
| AU (2) | AU2002366315A1 (es) |
| BR (2) | BR0214986A (es) |
| CA (2) | CA2469302A1 (es) |
| CY (2) | CY1106276T1 (es) |
| DE (2) | DE60214594T2 (es) |
| DK (2) | DK1458673T3 (es) |
| ES (2) | ES2271381T3 (es) |
| HU (2) | HUP0402133A3 (es) |
| IL (3) | IL162331A0 (es) |
| IS (2) | IS7309A (es) |
| MX (2) | MXPA04006004A (es) |
| MY (1) | MY132565A (es) |
| NO (2) | NO20043023L (es) |
| NZ (2) | NZ533274A (es) |
| PL (2) | PL370673A1 (es) |
| PT (2) | PT1458672E (es) |
| RU (2) | RU2300517C2 (es) |
| SE (1) | SE0104334D0 (es) |
| SI (2) | SI1458673T1 (es) |
| TW (2) | TWI253444B (es) |
| UA (2) | UA77987C2 (es) |
| WO (2) | WO2003051821A1 (es) |
| ZA (2) | ZA200404657B (es) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE281432T1 (de) | 1999-03-05 | 2004-11-15 | Univ Duke | C-16 ungesätigte fp-selektive prostaglandin analoge |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
| SE0104333D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| GB0229931D0 (en) * | 2002-12-21 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| GB0314079D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| SE0104334D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| GB0209467D0 (en) * | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| US7220880B2 (en) | 2002-06-19 | 2007-05-22 | Eli Lilly And Company | Amide linker peroxisome proliferator activated receptor modulators |
| EP1517883B8 (en) | 2002-06-20 | 2008-05-21 | AstraZeneca AB | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance |
| FR2848452B1 (fr) * | 2002-12-12 | 2007-04-06 | Aventis Pharma Sa | Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer |
| EP1599468B1 (en) | 2003-01-14 | 2007-10-03 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
| GB0314134D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314136D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314129D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| AR045697A1 (es) | 2003-07-14 | 2005-11-09 | Arena Pharm Inc | Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo |
| JP2007512347A (ja) * | 2003-11-26 | 2007-05-17 | デューク・ユニバーシティー | 緑内障を予防するかまたは治療する方法 |
| AU2004303793A1 (en) * | 2003-12-15 | 2005-07-07 | Eli Lilly And Company | Selective peroxisome proliferator activated receptor modulators |
| MX2007001634A (es) * | 2004-08-11 | 2007-04-23 | Kyorin Seiyaku Kk | Nuevo derivado de acido amino benzoico ciclico. |
| SE0403072D0 (sv) * | 2004-12-16 | 2004-12-16 | Astrazeneca Ab | Pharmaceutically useful salts of carboxylic acid derivates |
| ES2382876T3 (es) | 2005-05-31 | 2012-06-14 | Pfizer, Inc. | Compuestos de ariloxi-N-biciclometil-acetamida sustituidos como antagonistas de VR1 |
| WO2007004957A1 (en) * | 2005-07-05 | 2007-01-11 | Astrazeneca Ab | Novel crystalline form |
| AR055073A1 (es) * | 2005-07-11 | 2007-08-01 | Astrazeneca Ab | Agentes terapeuticos |
| TWI331523B (en) * | 2005-12-08 | 2010-10-11 | Nat Health Research Institutes | Vinylsulfonate compounds |
| CN101054372B (zh) * | 2006-04-11 | 2010-10-13 | 中国科学院上海药物研究所 | 嘧啶取代苯丙酸衍生化合物、其制法和在治疗多囊肾疾病中的用途 |
| KR100847780B1 (ko) * | 2006-10-26 | 2008-07-23 | 재단법인서울대학교산학협력재단 | 2-에톡시프로피온산 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로함유하는 당뇨병 예방 및 치료제 |
| RU2361581C2 (ru) | 2007-09-14 | 2009-07-20 | Закрытое Акционерное Общество "Мастерклон" | Фармацевтическая композиция, обладающая противодиабетической, гиполипидемической, гипогликемической и гипохолестеринемической активностью, способ ее получения и способы лечения указанных заболеваний |
| US20110293549A1 (en) | 2009-02-03 | 2011-12-01 | Athena Cosmetics, Inc. | Composition, method and kit for enhancing hair |
| AU2011305525B2 (en) | 2010-09-22 | 2016-08-18 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
| LT2637668T (lt) | 2010-11-04 | 2016-09-12 | Albireo Ab | Ibat inhibitoriai kepenų ligoms gydyti |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| KR20220082931A (ko) | 2014-06-25 | 2022-06-17 | 이에이 파마 가부시키가이샤 | 고형 제제 및 그의 착색 방지 또는 착색 감소 방법 |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| CN116850181A (zh) | 2015-01-06 | 2023-10-10 | 艾尼纳制药公司 | 治疗与s1p1受体有关的病症的方法 |
| AU2016284162A1 (en) | 2015-06-22 | 2018-02-01 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in SIP1 receptor-associated disorders |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| AU2018220521A1 (en) | 2017-02-16 | 2019-09-05 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| WO2019032026A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | CHOLESTYRAMINE GRANULES, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE |
| CN112449637B (zh) | 2018-06-05 | 2024-03-19 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2019236757A1 (en) | 2018-06-06 | 2019-12-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
| MY209425A (en) | 2018-06-20 | 2025-07-08 | Albireo Ab | Crystal modifications of odevixibat |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| HRP20230039T1 (hr) | 2019-02-06 | 2023-06-09 | Albireo Ab | Benzotiadiazepinski spojevi i njihova uporaba kao modulatora žučnih kiselina |
| ES2973355T3 (es) | 2019-12-04 | 2024-06-19 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar |
| ES2972045T3 (es) | 2019-12-04 | 2024-06-10 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| CR20220315A (es) | 2019-12-04 | 2022-10-26 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores del ácido biliar |
| ES3029063T3 (en) | 2019-12-04 | 2025-06-23 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| EP4188541B1 (en) | 2020-08-03 | 2024-12-25 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| AU2021379076A1 (en) | 2020-11-12 | 2023-06-08 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
| CA3198216A1 (en) | 2020-12-04 | 2022-06-09 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| WO2023039276A1 (en) * | 2021-09-13 | 2023-03-16 | Curtails Llc | Use of ibat inhibitors and antimicrobials for the treatment of diseases |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE266121C (es) | ||||
| BE489216A (es) | 1948-06-05 | 1900-01-01 | ||
| US2928840A (en) | 1958-11-26 | 1960-03-15 | Us Vitamin Pharm Corp | 3-(o-substituted phenyl) oxazolidinediones and process therefor |
| GB1081471A (en) | 1963-09-13 | 1967-08-31 | Stauffer Chemical Co | Glycol amide derivatives and use thereof in controlling weed growth |
| US3244398A (en) | 1963-10-28 | 1966-04-05 | Scaramucci Domer | Composite seat ball valve |
| AT307640B (de) | 1970-06-18 | 1973-05-25 | Richter Gedeon Vegyeszet | Verfahren zur Herstellung von neuen 17-Aza-steroiden und deren Salzen |
| BE792364A (fr) | 1971-12-06 | 1973-06-06 | Basf Ag | Derives de substitution du sulfonylglycolanilide |
| DE2349256C2 (de) | 1973-10-01 | 1985-08-01 | Basf Ag, 6700 Ludwigshafen | 0-Alkylsulfonyl-glykolsäureanilide und diese enthaltende Herbizide |
| DE2828222A1 (de) | 1978-06-28 | 1980-01-10 | Bayer Ag | Gegenmittel zum schutz von kulturpflanzen vor schaedigungen durch herbizide |
| US4735959A (en) | 1981-01-10 | 1988-04-05 | Dr. Karl Thomae Gmbh | Carboxylic acid amides and pharmaceutical compositions containing them |
| US5312924A (en) | 1983-12-30 | 1994-05-17 | Dr. Karl Thomae Gmbh | Phenylacetic acid benzylamides |
| US5216167A (en) | 1983-12-30 | 1993-06-01 | Dr. Karl Thomae Gmbh | Phenylacetic acid benzylamides |
| US5210208A (en) | 1990-09-24 | 1993-05-11 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Disubstituted aryl compounds exhibiting selective leukotriene b4 antagonist activity |
| US5958792A (en) | 1995-06-07 | 1999-09-28 | Chiron Corporation | Combinatorial libraries of substrate-bound cyclic organic compounds |
| DE69824433D1 (en) | 1997-08-28 | 2004-07-15 | Biovitrum Ab | Proteintyrosinphosphatase inhibitoren |
| US6410585B1 (en) | 1997-08-28 | 2002-06-25 | Scott D. Larsen | Inhibitors of protein tyrosine phosphatase |
| US6576766B1 (en) | 1997-11-12 | 2003-06-10 | Ariad Pharmaceuticals, Inc. | Signal transduction inhibitors, compositions containing them |
| SE9801992D0 (sv) | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
| MXPA01010109A (es) | 1999-04-06 | 2002-06-04 | Sankyo Co | Derivados de acido carboxilico alfasustituidos. |
| AU3670900A (en) * | 1999-04-08 | 2000-11-14 | Sankyo Company Limited | Substituted fused imidazole derivatives |
| AU4278400A (en) | 1999-04-14 | 2000-11-14 | University Of British Columbia, The | Improved beta,beta,-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins |
| AU3958200A (en) | 1999-04-20 | 2000-11-02 | Novo Nordisk A/S | New compounds, their preparation and use |
| EE200100556A (et) | 1999-04-28 | 2003-02-17 | Aventis Pharma Deutschland Gmbh | Diarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi kasutamine ravimite valmistamiseks |
| JP4618845B2 (ja) * | 1999-06-09 | 2011-01-26 | 杏林製薬株式会社 | ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体 |
| TWI262185B (en) | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
| JP2001261612A (ja) | 2000-03-22 | 2001-09-26 | Mitsui Chemicals Inc | カテコールプロピオン酸誘導体およびそれを有効成分として含有する核内レセプター作動薬 |
| AU2002222552A1 (en) | 2000-11-29 | 2002-06-11 | Kyorin Pharmaceutical Co. Ltd. | Substituted carboxylic acid derivatives |
| JPWO2002044130A1 (ja) | 2000-11-29 | 2004-04-02 | 杏林製薬株式会社 | 置換カルボン酸誘導体 |
| EP1360172A1 (en) | 2001-02-15 | 2003-11-12 | Pfizer Products Inc. | Ppar agonists |
| WO2002083616A1 (en) * | 2001-04-10 | 2002-10-24 | Sankyo Company, Limited | α-SUBSTITUTED φ-ARYLFATTY ACID DERIVATIVE |
| SE0104334D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| GB0229931D0 (en) | 2002-12-21 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| GB0314079D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| US7220880B2 (en) | 2002-06-19 | 2007-05-22 | Eli Lilly And Company | Amide linker peroxisome proliferator activated receptor modulators |
| GB0314134D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314136D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314129D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
-
2001
- 2001-12-19 SE SE0104334A patent/SE0104334D0/xx unknown
-
2002
- 2002-12-18 US US10/499,261 patent/US7514471B2/en not_active Expired - Fee Related
- 2002-12-18 PL PL02370673A patent/PL370673A1/xx not_active Application Discontinuation
- 2002-12-18 BR BR0214986-9A patent/BR0214986A/pt not_active IP Right Cessation
- 2002-12-18 CA CA002469302A patent/CA2469302A1/en not_active Abandoned
- 2002-12-18 IL IL16233102A patent/IL162331A0/xx unknown
- 2002-12-18 EP EP02804964A patent/EP1458673B1/en not_active Expired - Lifetime
- 2002-12-18 HU HU0402133A patent/HUP0402133A3/hu unknown
- 2002-12-18 PT PT02788145T patent/PT1458672E/pt unknown
- 2002-12-18 TW TW091136518A patent/TWI253444B/zh not_active IP Right Cessation
- 2002-12-18 MX MXPA04006004A patent/MXPA04006004A/es active IP Right Grant
- 2002-12-18 AT AT02804964T patent/ATE338743T1/de not_active IP Right Cessation
- 2002-12-18 RU RU2004116918/04A patent/RU2300517C2/ru not_active IP Right Cessation
- 2002-12-18 SI SI200230424T patent/SI1458673T1/sl unknown
- 2002-12-18 UA UA20040604245A patent/UA77987C2/uk unknown
- 2002-12-18 NZ NZ533274A patent/NZ533274A/en unknown
- 2002-12-18 IL IL16233002A patent/IL162330A0/xx unknown
- 2002-12-18 KR KR10-2004-7009517A patent/KR20040074094A/ko not_active Ceased
- 2002-12-18 TW TW091136519A patent/TWI255807B/zh not_active IP Right Cessation
- 2002-12-18 KR KR10-2004-7009501A patent/KR20040074092A/ko not_active Withdrawn
- 2002-12-18 JP JP2003552709A patent/JP3784804B2/ja not_active Expired - Fee Related
- 2002-12-18 WO PCT/GB2002/005738 patent/WO2003051821A1/en not_active Ceased
- 2002-12-18 PL PL02370672A patent/PL370672A1/xx not_active Application Discontinuation
- 2002-12-18 MY MYPI20024740A patent/MY132565A/en unknown
- 2002-12-18 ES ES02804964T patent/ES2271381T3/es not_active Expired - Lifetime
- 2002-12-18 BR BR0214988-5A patent/BR0214988A/pt not_active IP Right Cessation
- 2002-12-18 HU HU0402022A patent/HUP0402022A3/hu unknown
- 2002-12-18 JP JP2003552710A patent/JP3820249B2/ja not_active Expired - Lifetime
- 2002-12-18 WO PCT/GB2002/005744 patent/WO2003051822A1/en not_active Ceased
- 2002-12-18 CN CNB028281233A patent/CN1293044C/zh not_active Expired - Fee Related
- 2002-12-18 AT AT02788145T patent/ATE363466T1/de not_active IP Right Cessation
- 2002-12-18 DE DE60214594T patent/DE60214594T2/de not_active Expired - Lifetime
- 2002-12-18 SI SI200230570T patent/SI1458672T1/sl unknown
- 2002-12-18 MX MXPA04006003A patent/MXPA04006003A/es active IP Right Grant
- 2002-12-18 AU AU2002366315A patent/AU2002366315A1/en not_active Abandoned
- 2002-12-18 CN CNA028281551A patent/CN1620423A/zh active Pending
- 2002-12-18 US US10/499,378 patent/US7256307B2/en not_active Expired - Fee Related
- 2002-12-18 CN CNB2006100071731A patent/CN100406427C/zh not_active Expired - Fee Related
- 2002-12-18 UA UA20040604246A patent/UA77460C2/uk unknown
- 2002-12-18 NZ NZ533276A patent/NZ533276A/en unknown
- 2002-12-18 DK DK02804964T patent/DK1458673T3/da active
- 2002-12-18 RU RU2004116917/04A patent/RU2303031C2/ru not_active IP Right Cessation
- 2002-12-18 DE DE60220441T patent/DE60220441T2/de not_active Expired - Fee Related
- 2002-12-18 CA CA002470491A patent/CA2470491A1/en not_active Abandoned
- 2002-12-18 ES ES02788145T patent/ES2286310T3/es not_active Expired - Lifetime
- 2002-12-18 DK DK02788145T patent/DK1458672T3/da active
- 2002-12-18 PT PT02804964T patent/PT1458673E/pt unknown
- 2002-12-18 EP EP02788145A patent/EP1458672B1/en not_active Expired - Lifetime
- 2002-12-18 AU AU2002352427A patent/AU2002352427A1/en not_active Abandoned
- 2002-12-19 AR ARP020105004A patent/AR038047A1/es not_active Application Discontinuation
- 2002-12-19 AR ARP020105002A patent/AR038045A1/es unknown
-
2004
- 2004-06-03 IL IL162330A patent/IL162330A/en not_active IP Right Cessation
- 2004-06-11 ZA ZA200404657A patent/ZA200404657B/en unknown
- 2004-06-11 ZA ZA200404658A patent/ZA200404658B/en unknown
- 2004-06-14 IS IS7309A patent/IS7309A/is unknown
- 2004-06-15 IS IS7313A patent/IS7313A/is unknown
- 2004-07-15 NO NO20043023A patent/NO20043023L/no not_active Application Discontinuation
- 2004-07-16 NO NO20043164A patent/NO20043164L/no not_active Application Discontinuation
-
2005
- 2005-08-16 JP JP2005235794A patent/JP2005336209A/ja active Pending
-
2006
- 2006-04-27 JP JP2006123399A patent/JP2006298924A/ja active Pending
- 2006-12-05 CY CY20061101743T patent/CY1106276T1/el unknown
-
2007
- 2007-08-01 CY CY20071101028T patent/CY1106784T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA04006003A (es) | Derivados del acido fenilpropionico substituidos como agonistas al receptor alfa activado-proliferativo de peroxisoma (ppar) humano. | |
| SI1326613T1 (en) | Use of substituted imidazo 1,2-a)pyridine-, imidazo (1,2-a)pyrimidine and imidazo (1,2-a)pyrazine-3-yl-amine derivatives for producing nos-inhibiting medicaments | |
| NO20052914L (no) | Terapeutiske forbindelser | |
| MXPA05013712A (es) | Derivados de acido propionico, utiles en el tratamiento de trastornos de lipidos. | |
| UA66852C2 (uk) | Похідні та аналоги 3-арилпропіонової кислоти, спосіб їх отримання, фармацевтична композиція (варіанти) та спосіб профілактики та/або лікування асоційованих з резистентністю до інсуліну клінічних станів | |
| SE0202462D0 (sv) | Novel use | |
| MXPA04005444A (es) | Ureas de 2-aminobenzotiazoles como moduladores de adenosina. | |
| NZ515705A (en) | Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor (PPAR) alpha | |
| CO5271691A1 (es) | Nuevos compuestos | |
| AU2002359164A8 (en) | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | |
| WO2004026863A8 (en) | Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors | |
| IL166412A0 (en) | Novel use of benzothiazole derivatives | |
| PT1696905E (pt) | 2-aminotetralinas substituídas para o tratamento preventivo da doença de parkinson | |
| MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
| SE9903997D0 (sv) | New compounds | |
| MY135920A (en) | New phenalkyloxy-phenyl derivatives | |
| SE0302573D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| AU2002359162A1 (en) | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | |
| NZ336189A (en) | Diaza-spiro[3,5]nonane derivatives and use in treatment of diseases related to the orphanin receptor | |
| WO2004041802A8 (en) | 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders | |
| ATE366107T1 (de) | Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen | |
| NO20065078L (no) | Inhaleringspulver formuleringer inneholdende enantiomerisk rene beta-agonister. | |
| HUP0402515A2 (hu) | Szubsztituált új N-[4-(1H-imidazol-1-il)-2-fluor-fenil]-3-(trifluor-metil)-1H-pirazol-5-karboxamidok Xa faktor inhibitorok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
| SE0302572D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| SE0104333D0 (sv) | Therapeutic agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |